AAIC 2022 | Importance of standardizing biomarker protocols in the diagnosis of AD

Marc Suárez-Calvet, MD, PhD, Barcelonaβeta Brain Research Center (BBRC), Barcelona, Spain, addresses the importance of standardizing handling and processing protocols for the use of biomarkers in Alzheimer’s disease (AD). The implementation of cerebrospinal fluid (CSF)-based phosphorylated-tau assessment in clinics took a long time due to important issues with the preclinical aspects of biomarker measurement. This exemplifies the need for standardization of operating procedures for preanalytical methods to optimize the use of blood biomarkers in the early diagnosis of AD. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.